未登录 分享 收藏
分享 收藏
A CRUK phase I/IIA, first in human dose-escalation and expansion trial of HMBD-001 (an anti-HER3 antibody) in patients with advanced HER3 positive solid tumours de Bono, J. S.; Lord, S.; Yap, C.; Miranda, S.; Veal, G. J.; Chandran, K.; Paschalis, A.; Peron, C.; Rekowski, J.; Gurel, B.; Paisley, D.; McGuigan, L.; Ingram, P. J.; Kwek, K. Y.; Halbert, G.; Westwood, N. B.; Griffin, A. E.; Kostaras, L.; Boyd-Kirkup, J. D.; Walter, H. S. 分享 收藏
Anti-HER3 antibody, HMBD-001, in combination with an EGFR inhibitor effectively inhibits tumor growth in biomarker-selected pre-clinical models of squamous cell carcinomas Toy, Weiyi; Thakkar, Dipti; Luu, Khang; Chi, Bui Ngoc Linh; Lai, Jason; Ray, Debleena; Gandhi, Namita; Mas, Alejandro; Paszkiewicz, Konrad; Ingram, Piers; Boyd-Kirkup, Jerome 分享 收藏
HMBD-501-a novel Fc engineered, exatecan-based next generation HER3 targeting antibody drug conjugate shows robust efficacy and tolerability in pre-clinical solid tumor models Rasheed, Suhail Ahmed Kabeer; Thakkar, Dipti; Paliwal, Shalini; Chin, Wen Jie; Bansal, Akshaya; Ben Ayers; Ng, Che Theng; Hanson, Brendon; Ingram, Piers; Boyd-Kirkup, Jerome 分享 收藏
分享 收藏
TRIAL IN PROGRESS: A PHASE 1 FIRST-IN-HUMAN STUDY OF HMBD-002, AN IGG4 MONOCLONAL ANTIBODY TARGETING VISTA, AS A MONOTHERAPY AND COMBINED WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES Haber, Tom; Symons, Jessica; Dharmadhikari, Bhushan; Mueller, Thomas; Thakkar, Dipti; Rodon, Jordi Ahnert; Gruber, Joshua; Telli, Melinda; Mita, Monica; Mita, Alain; Patel, Meera; Wang, Daniel; Kim, Joseph; Yadav, Shalini; Sharma, Padmanee; DiMascio, Leah; Rowinsky, Eric; Ingram, Piers; Boyd-Kirkup, Jerome 分享 收藏
Rationally targeted anti-VISTA antibody that blockades the C-C' loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner Thakkar, Dipti; Paliwal, Shalini; Dharmadhikari, Bhushan; Guan, Siyu; Liu, Lillian; Kar, Shreya; Tulsian, Nikhil K.; Gruber, Joshua J.; DiMascio, Leah; Paszkiewicz, Konrad H.; Ingram, Piers J.; Boyd-Kirkup, Jerome D. 分享 收藏
An anti-HER3 antibody, HMBD-001, that uniquely binds to and blocks the HER3 heterodimerization interface, shows superior tumor growth inhibition in biomarker-defined preclinical cancer models including NRG1-fusion driven cancers Thakkar, Dipti; Paliwal, Shalini; Kar, Shreya; Gandhi, Namita; Paszkiewicz, Konrad; Ingram, Piers; Boyd-Kirkup, Jerome 分享 收藏
A PHASE 1 FIRST IN HUMAN STUDY OF HMBD-002, AN IGG4 MONOCLONAL ANTIBODY TARGETING VISTA, AS A MONOTHERAPY AND COMBINED WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES DiMascio, Leah; Thakkar, Dipti; Guan, Siyu; Rowinsky, Eric; Rodon, Jordi; Gruber, Joshua; Musher, Benjamin; Kim, Joseph; Mita, Alain; Mita, Monica; Ingram, Piers; Boyd-Kirkup, Jerome 分享 收藏
10D1F, an Anti-HER3 Antibody that Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models Thakkar, Dipti; Sancenon, Vicente; Taguiam, Marvin M.; Guan, Siyu; Wu, Zhihao; Ng, Eric; Paszkiewicz, Konrad H.; Ingram, Piers J.; Boyd-Kirkup, Jerome D. 分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
.png){kind=icon}
未登录.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
